Month: October 2024

Neo-AEGIS Study Unveils: Peroperative Chemo Stands Tall in Esophageal Cancer Treatment, Signaling a Customized Future Editor's Note: From September 22nd to 24th, 2024, the 20th International Esophageal Cancer Conference (ISDE) took place in Edinburgh, Scotland. The Neo-AEGIS study, which compared the efficacy of perioperative chemotherapy with the CROSS regimen (preoperative chemotherapy combined with radiotherapy) in the treatment of esophageal cancer, captured global attention. As the corresponding author of the study, Dr. John Reynolds from St. James's Hospital in Ireland provided an in-depth interpretation of the research findings and discussed their profound impact on future strategies for esophageal cancer treatment.

The 20th International Society for Diseases of the Esophagus (ISDE) conference took place in Edinburgh, Scotland, from September 22nd to 24th, 2024. At the conference, a study by Dr. Krishna Moorthy from the Royal College of Surgeons in the UK on whether prehabilitation can increase the surgical opportunities for esophageal cancer patients was selected for presentation (Abstract No.: S19.02). Oncology Frontier conducted an exclusive interview with Professor Moorthy at the conference venue about this research. The interview content has been organized and the relevant study abstract is attached for reference.

From September 26 to 28, 2024, the China Anti-Cancer Association (CACA) and the CACA Integrative Esophageal Cancer Committee hosted the 2024 CACA Integrative Esophageal Cancer Academic Conference in Hefei. The conference, under the theme “Winning in Integration for Cancer Prevention and Treatment,” gathered the latest research developments and clinical experiences from experts in esophageal cancer worldwide. During the event, Oncology Frontier had the opportunity to interview Dr. Liu Hong from The First Affiliated Hospital of Air Force Medical University (Xijing Hospital). In this interview, Professor Hong delves into the trends of integrative treatment, individualized care, and the importance of comprehensive patient management. Below is the full transcript of the interview for our readers.

From September 25 to 29, 2024, the highly anticipated 27th National Clinical Oncology Conference and CSCO Annual Meeting was successfully held in Xiamen. This prestigious event brought together top experts in the field of oncology from across China, focusing on standardized pathways for diagnosis and treatment of malignant tumors and exploring the latest frontiers. During the conference, Dr. Jun Zhou from Peking University Cancer Hospital delivered a presentation titled “Advances in the Application of New Anticancer Drugs in Biliary Tract Cancer” at the dedicated session on targeted therapy for cholangiocarcinoma. Oncology Frontier had the opportunity to conduct an in-depth interview with Professor Zhou, delving into the current progress in drug treatments for biliary tract cancers and exploring future research directions.

Soft tissue sarcoma (STS) is a highly heterogeneous group of tumors with complex pathology, and the benefits of first-line chemotherapy, primarily anthracycline-based, are limited. As a result, patient prognosis remains poor overall. In recent years, anti-angiogenic tyrosine kinase inhibitors (TKIs) have emerged as a promising option for second- and later-line treatments, with potential for expansion into the first-line setting. At the 2024 CSCO conference, Dr. Yuhong Zhou from Zhongshan Hospital, Fudan University, delivered a detailed presentation on the latest research in anti-angiogenic TKIs for STS. In an exclusive interview with Oncology Frontier, she also shared insights into the advancements in diagnosis and treatment in this field.

In a special interview at the 20th International Society for Diseases of the Esophagus (ISDE) conference, Dr. Jens Hoeppner from Bielefeld University in Germany shared his insights on the FLOT regimen's clinical benefits over the CROSS regimen in the treatment of locally advanced resectable esophageal adenocarcinoma. He also discussed the potential integration of immunotherapy and the 'watch and wait' strategy in future treatments.